who discovered glp 1 Timeline of GLP-1 discovery and clinical development. (a) Key events in Who should win a Nobel

doi: 10.1111/j.1463-1326.2012.01676.x

Urine panels specifically target metabolites and parent compounds of controlled substances excreted through the kidneys

However, the exact mechanisms underlying these effects remain unclear, particularly whether the cognitive improvements are a direct result of GLP-1 action or are mediated indirectly via enhanced glucose regulation

Current advanced therapies for moderate to severe IBDs such as biologic agents (anti-TNF, anti IL12/23, anti-IL-23, and anti-integrins) and small molecules (JAK inhibitors and anti-S1P) have improved the therapeutic armamentarium available to IBD physicians, however, their use is limited by adverse effects, high costs, and a ceiling of effectiveness

Pipeline Activity The pipeline for GLP-1 and related metabolic disease treatments is extremely active